Skip to main content
. 2018 Jun 5;20(9):2121–2130. doi: 10.1111/dom.13340

Figure 2.

Figure 2

Efficacy and safety outcome measures through the treatment period. A, Change in glycated haemoglobin (HbA1c) from baseline to 26 weeks. aLeast Square Mean (LSM) difference (95% confidence interval [CI]) of dulaglutide 1.5 mg with glimepiride. bLSM difference (95% CI) of dulaglutide 0.75 mg with glimepiride. *Dulaglutide non‐inferior to glimepiride (1‐sided P value <.001). †Dulaglutide superior to glimepiride (2‐sided P value <.001). B, Change in HbA1c from baseline over time. C, Percentage of patients achieving HbA1c targets at week 26. *P < .001 dulaglutide vs glimepiride. D, Change in fasting blood glucose (FBG) from baseline to week 26. aLSM difference (95% CI) of dulaglutide 1.5 mg with glimepiride. bLSM difference (95% CI) of dulaglutide 0.75 mg with glimepiride. * P < .001 dulaglutide vs glimepiride. † P < .05 dulaglutide vs glimepiride. E, Seven‐point self‐monitored blood glucose (SMBG) profiles by time of day. PP, postprandial. *P < .001 dulaglutide vs glimepiride. † P < .05 dulaglutide vs glimepiride. F, Change in body weight from baseline to 26 weeks. *P < .001 dulaglutide vs glimepiride. † P < .05 dulaglutide vs glimepiride. Abbreviation: SE, standard error